丙型肝炎治疗失败：无应答机制
Treatment failure in hepatitis C: mechanisms of non-response.
作者信息
Tai Andrew W, Chung Raymond T
机构信息
Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, WRN 1007, 55 Fruit Street, Boston, MA 02114, USA.
出版信息
J Hepatol. 2009 Feb;50(2):412-20. doi: 10.1016/j.jhep.2008.11.010. Epub 2008 Dec 3.
Abstract
Hepatitis C virus (HCV) has evolved remarkable mechanisms that favor viral persistence by interfering with host innate and adaptive immune responses. These same mechanisms are likely to contribute to resistance to exogenously administered interferon used for HCV treatment. We review the host innate and adaptive immune responses in the context of HCV infection as well as the strategies by which these responses are subverted by the virus. In addition, the contribution of host factors, such as race and insulin resistance, to interferon non-responsiveness is discussed. Our progress in understanding the molecular underpinnings of interferon treatment failure in HCV infection has resulted in several promising and novel treatment strategies for HCV treatment non-responders.
摘要
丙型肝炎病毒（HCV）已经进化出了显著的机制，通过干扰宿主的先天性和适应性免疫反应来促进病毒的持续存在。这些相同的机制可能导致对用于HCV治疗的外源性干扰素产生耐药性。我们回顾了HCV感染背景下宿主的先天性和适应性免疫反应，以及病毒颠覆这些反应的策略。此外，还讨论了宿主因素，如种族和胰岛素抵抗，对干扰素无反应性的影响。我们在理解HCV感染中干扰素治疗失败的分子基础方面取得的进展，已经为HCV治疗无反应者带来了几种有前景的新型治疗策略。
相似文献
1
Treatment failure in hepatitis C: mechanisms of non-response.丙型肝炎治疗失败：无应答机制
J Hepatol. 2009 Feb;50(2):412-20. doi: 10.1016/j.jhep.2008.11.010. Epub 2008 Dec 3.
2
Innate and adaptive immune responses in HCV infections.HCV 感染中的固有和适应性免疫反应。
J Hepatol. 2014 Nov;61(1 Suppl):S14-25. doi: 10.1016/j.jhep.2014.06.035. Epub 2014 Nov 3.
3
Interaction of hepatitis C virus with the type I interferon system.丙型肝炎病毒与I型干扰素系统的相互作用。
World J Gastroenterol. 2007 Sep 28;13(36):4818-23. doi: 10.3748/wjg.v13.i36.4818.
4
The dynamic relationship between innate immune biomarkers and interferon-based treatment effects and outcome in hepatitis C virus infection is altered by telaprevir.特拉匹韦改变了丙型肝炎病毒感染中固有免疫生物标志物与基于干扰素的治疗效果及转归之间的动态关系。
PLoS One. 2014 Aug 28;9(8):e105665. doi: 10.1371/journal.pone.0105665. eCollection 2014.
5
Innate immune responses in hepatitis C virus infection.丙型肝炎病毒感染中的固有免疫应答。
Semin Immunopathol. 2013 Jan;35(1):53-72. doi: 10.1007/s00281-012-0332-x. Epub 2012 Aug 7.
6
Hepatitis C Virus Infection: Host⁻Virus Interaction and Mechanisms of Viral Persistence.丙型肝炎病毒感染：宿主-病毒相互作用和病毒持续存在的机制。
Cells. 2019 Apr 25;8(4):376. doi: 10.3390/cells8040376.
7
Modelling how ribavirin improves interferon response rates in hepatitis C virus infection.模拟利巴韦林如何提高丙型肝炎病毒感染中的干扰素反应率。
Nature. 2004 Dec 16;432(7019):922-4. doi: 10.1038/nature03153.
8
Variation in both IL28B and KIR2DS3 genes influence pegylated interferon and ribavirin hepatitis C treatment outcome in HIV-1 co-infection.IL28B 和 KIR2DS3 基因的变异均影响 HIV-1 合并感染患者聚乙二醇干扰素和利巴韦林治疗丙型肝炎的效果。
PLoS One. 2013 Jun 24;8(6):e66831. doi: 10.1371/journal.pone.0066831. Print 2013.
9
Innate immunity and HCV.先天免疫与丙型肝炎病毒。
J Hepatol. 2013 Mar;58(3):564-74. doi: 10.1016/j.jhep.2012.10.005. Epub 2012 Oct 11.
10
Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview.丙型肝炎病毒异质性对干扰素敏感性的影响：综述
World J Gastroenterol. 2014 Jun 28;20(24):7555-69. doi: 10.3748/wjg.v20.i24.7555.
引用本文的文献
1
Impact of IL-10 gene promoter polymorphisms on treatment response in HCV patients: A systematic review, a meta-analysis, and a meta-regression.IL-10 基因启动子多态性对 HCV 患者治疗反应的影响：系统评价、荟萃分析和荟萃回归。
Int J Immunopathol Pharmacol. 2024 Jan-Dec;38:3946320241240705. doi: 10.1177/03946320241240705.
2
Host-Directed Antiviral Therapy.宿主导向性抗病毒治疗
Clin Microbiol Rev. 2020 May 13;33(3). doi: 10.1128/CMR.00168-19. Print 2020 Jun 17.
3
A Long Noncoding RNA Regulates Hepatitis C Virus Infection Through Interferon Alpha-Inducible Protein 6.一种长非编码 RNA 通过干扰素诱导蛋白 6 调控丙型肝炎病毒感染。
Hepatology. 2019 Mar;69(3):1004-1019. doi: 10.1002/hep.30266. Epub 2019 Feb 13.
4
Analysis of TLR7, SOCS1 and ISG15 immune genes expression in the peripheral blood of responder and non-responder patients with chronic Hepatitis C.慢性丙型肝炎应答者和无应答者患者外周血中TLR7、SOCS1和ISG15免疫基因表达的分析
Gastroenterol Hepatol Bed Bench. 2017 Fall;10(4):272-277.
5
Asunaprevir Evokes Hepatocytes Innate Immunity to Restrict the Replication of Hepatitis C and Dengue Virus.asunaprevir激发肝细胞固有免疫以限制丙型肝炎病毒和登革病毒的复制。
Front Microbiol. 2017 Apr 20;8:668. doi: 10.3389/fmicb.2017.00668. eCollection 2017.
6
Analysis of mutations in the core and NS5A genes of hepatitis C virus in non-responder and relapser patients after treatment with Peg-IFN-α and ribavirin.聚乙二醇干扰素α和利巴韦林治疗后无应答和复发患者丙型肝炎病毒核心基因和NS5A基因突变分析
Virusdisease. 2016 Mar;27(1):55-62. doi: 10.1007/s13337-015-0300-x. Epub 2016 Jan 18.
7
Update on the Development of Anti-Viral Agents Against Hepatitis C.抗丙型肝炎病毒药物的研究进展。
J Clin Transl Hepatol. 2013 Sep;1(1):9-21. doi: 10.14218/JCTH.2013.007XX. Epub 2013 Sep 15.
8
New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A.利用离子载体莫能菌素A对丙型肝炎病毒进入及细胞间传播的新认识
J Virol. 2015 Aug;89(16):8346-64. doi: 10.1128/JVI.00192-15. Epub 2015 Jun 3.
9
Model-guided therapy for hepatocellular carcinoma: a role for information technology in predictive, preventive and personalized medicine.基于模型的肝细胞癌治疗：信息技术在预测性、预防性和个体化医学中的作用。
EPMA J. 2014 Sep 23;5(1):16. doi: 10.1186/1878-5085-5-16. eCollection 2014.
10
Prevention of hepatitis C virus infection by adoptive allogeneic immunotherapy using suicide gene-modified lymphocytes: an in vitro proof-of-concept.采用自杀基因修饰淋巴细胞的过继性同种异体免疫疗法预防丙型肝炎病毒感染：一项体外概念验证研究
Gene Ther. 2015 Feb;22(2):172-80. doi: 10.1038/gt.2014.99. Epub 2014 Nov 13.
本文引用的文献
1
Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors.丙型肝炎蛋白酶和聚合酶抑制剂对RIG-I信号的抗病毒抑制与恢复作用
Gastroenterology. 2008 Nov;135(5):1710-1718.e2. doi: 10.1053/j.gastro.2008.07.023. Epub 2008 Jul 22.
2
Treatment predictors of a sustained virologic response in hepatitis B and C.乙型和丙型肝炎病毒持续病毒学应答的治疗预测因素
J Hepatol. 2008 Oct;49(4):634-51. doi: 10.1016/j.jhep.2008.07.013. Epub 2008 Jul 31.
3
Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C.干扰素信号通路基因和干扰素刺激基因中的单核苷酸多态性与慢性丙型肝炎干扰素治疗反应的关联
J Hepatol. 2008 Aug;49(2):184-91. doi: 10.1016/j.jhep.2008.04.011. Epub 2008 May 20.
4
Interferon signaling and treatment outcome in chronic hepatitis C.慢性丙型肝炎中的干扰素信号传导与治疗结果
Proc Natl Acad Sci U S A. 2008 May 13;105(19):7034-9. doi: 10.1073/pnas.0707882105. Epub 2008 May 8.
5
Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection.聚乙二醇干扰素在丙型肝炎病毒1型感染的非裔美国人和高加索裔美国人患者中的药代动力学。
Clin Gastroenterol Hepatol. 2008 May;6(5):575-83. doi: 10.1016/j.cgh.2008.02.035. Epub 2008 Apr 14.
6
The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus.亲环蛋白抑制剂Debio-025在丙型肝炎和人类免疫缺陷病毒合并感染患者中显示出强效的抗丙型肝炎作用。
Hepatology. 2008 Mar;47(3):817-26. doi: 10.1002/hep.22131.
7
Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response.聚乙二醇干扰素和利巴韦林治疗期间的肝脏基因表达：确定治疗反应的分子途径。
Hepatology. 2007 Nov;46(5):1548-63. doi: 10.1002/hep.21853.
8
Protection of hepatocytes from cytotoxic T cell mediated killing by interferon-alpha.干扰素-α对细胞毒性 T 细胞介导的肝细胞杀伤作用的保护。
PLoS One. 2007 Aug 29;2(8):e791. doi: 10.1371/journal.pone.0000791.
9
Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy.非裔美国人丙型肝炎病毒特异性免疫的选择性降低与抗病毒治疗结果
Hepatology. 2007 Aug;46(2):350-8. doi: 10.1002/hep.21714.
10
Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha.聚乙二醇干扰素、利巴韦林和α-促红细胞生成素治疗慢性丙型肝炎病毒1型感染
Hepatology. 2007 Aug;46(2):371-9. doi: 10.1002/hep.21712.
Zotero 插件